GlassScriptPhysician profile
David A Gloor
NPI 1942203732
$1,352.93
in general payments reported to CMS, 2019-2025
19 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $70.67 · 2021: $158 · 2022: $188 · 2023: $207 · 2024: $378 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.16 | 2021-2025 | |
| Amgen INC. | $142.61 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.91 | 2019-2022 | |
| Novo Nordisk INC | $102.95 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $100.79 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $70.31 | 2021-2024 | |
| Covidien LP | $63.50 | 2019 | |
| Abbott Laboratories | $55.87 | 2022-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $55.04 | 2023-2025 | Veozah |
| Lilly USA, LLC | $54.93 | 2022-2024 | Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $46.77 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $40.40 | 2020-2021 | |
| Medtronic, INC. | $34.78 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.22 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $27.78 | 2024 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $15.91 | 2024 | Injectafer |
| Glaxosmithkline, LLC. | $15.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.13 | 2022 | |
| Dexcom, INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gloor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.